AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Regulator of nonsense transcripts 3B

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library distinguishes itself through several key aspects:

  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9BZI7

UPID:

REN3B_HUMAN

Alternative names:

Nonsense mRNA reducing factor 3B; Up-frameshift suppressor 3 homolog B; Up-frameshift suppressor 3 homolog on chromosome X

Alternative UPACC:

Q9BZI7; D3DWI3; D3DWI4; Q0VAK8; Q9H1J0

Background:

Regulator of nonsense transcripts 3B (RNT3B), also known as Nonsense mRNA reducing factor 3B, plays a crucial role in the nonsense-mediated decay (NMD) pathway. It is pivotal in degrading mRNAs with premature stop codons, thus preventing the synthesis of truncated, potentially harmful proteins. RNT3B functions by associating with the nuclear exon junction complex and recruiting UPF2 to activate NMD, showcasing its essential role in maintaining mRNA quality control.

Therapeutic significance:

RNT3B's involvement in Intellectual developmental disorder, X-linked, syndromic 14, highlights its therapeutic potential. Understanding RNT3B's mechanisms could pave the way for innovative treatments targeting genetic disorders caused by nonsense mutations, offering hope for patients with this and potentially other related conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.